ライフサイエンスコーパス: 125I

1 125I-CPT-L2-BA3 was rapidly internalized by cells expres

2 125I-Cry4Ba toxin bound AgCad1 from S2 cells in a compet

3 125I-f-Alb could not be completely inhibited by MAA-Alb.

4 125I-HA binding to both the 175-kDa and 300-kDa HARE pro

5 125I-HA was taken up and degraded by excised rat livers

6 125I-Hst 5 binding assays showed saturable binding (Kd =

7 125I-Labeled annexin II binding assays with PSV10 cells

8 125I-labeled rh-FcgammaRIA was cleared from mouse blood

9 125I-mAb 30B3 uptake in IPL was rapid (T1/2 15 min), sat

10 125I-ox-LDL exhibited high affinity, saturable binding t

11 125I-Relaxin-3 binds GPCR135 at high affinity with a Kd

12 125I-TGF-beta1 affinity labeling analysis of cell-surfac

13 [125I]A-312110 is a useful tool for investigation of the

14 [125I]BDNF release was also modulated by 5HT(3) receptor

15 [125I]IAmF photolabeling of recombinant VMAT2, expressed

16 [125I]TID photoincorporated into both alpha4 and beta2 su

17 s and placement of radioactive iodine I 125 (125I)-labeled seeds in 10 patients.

18 -insoluble 2-(2',4'-dihydroxyphenyl)-6-[127I/125I]iodo-4-(3H)-quinazolinone (127IQ2-OH,4-OH (2)/125IQ

19 methanesulfonothioic acid, S-((4-(4-amino-3-[125I]iodobenzoyl) phenyl)methyl) ester.

20 e dissociation of the agonist N6-(4-amino-3-[125I]iodobenzyl)-5'-N-methylcarboxamidoadenosine from hu

21 cocaine analog 2beta-carbomethoxy-3beta-(4-[125I]iodophenyl)tropane (beta-CIT) in intact cells expre

22 cocaine analog 2beta-carbomethoxy-3beta-(4-[125I]iodophenyl)tropane.

23 -deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-[125I] iodouracil ([125I]FIAU) within bacteria.

24 Over 2 h, 36.9+/-4.6% 125I-T4 was recovered in cisternal CSF.

25 Competition for 125I-ABOPX (125I-3-(4-amino-3-iodobenzyl)-8-(phenyl-4-oxyacetate)-1-

26 gated mAb 30B3 with a plasminogen activator, 125I-tPA.

27 In addition, 125I-IGFBP-3 affinity-labeled TbetaR-V in Mv1Lu cells is

28 the caudate and putamen, but did not affect 125I-alpha-CtxMII sites.

29 WAY-161503 displaced both agonist ([125I]2,5-dimethoxy-4-iodoamphetamine (DOI)) and antagoni

30 inding assays, 125I-N6-aminobenzyladenosine (125I-ABA) binds to two affinity states of A1AR with KD-h

31 hotoactivatable irreversible cocaine analog [125I]3beta-(p-chlorophenyl)tropane-2beta-carboxylic acid

32 ave developed the novel radiolabeled analog [125I]-DNP and used this to localize high-affinity (K(D)=

33 -actin final concentration) as the analogous 125I-labeled F-actin blot overlay.

34 Here we used fluorescein ET-1 and 125I-ET-1 to provide evidence for ET-1 receptors in card

35 (2.9%) compared with 177Lu-BBN8 (15.9%) and 125I-[Tyr4]-BBN (46.1%).

36 177Lu-AMBA (76.8%), 177Lu-BBN8 (72.9%), and 125I-[Tyr4]-BBN (74.9%).

37 In the presence of [2,8-3H]ATP and 125I-Nedd8, heterodimer rapidly forms a stable stoichiom

38 nist, inhibits binding of 125I-TGF-beta1 and 125I-IGFBP-3 to TbetaR-V and diminishes IGFBP-3-induced

39 [3H]Cytisine and 125I-alpha-bungarotoxin binding sites were eliminated by

40 -N-propylamine] tetralin (3H-8-OH-DPAT), and 125I-RTI-55 was used to map the distribution and develop

41 es of 125I-low density lipoprotein (LDL) and 125I-high density lipoprotein 3 binding (HDL3).

42 s confirmed using recombinant paramyosin and 125I-CaGC.

43 tive binding experiments using unlabeled and 125I-M12A generated an IC50 of 0.71 nm and indicated tha

44 tibodies immunoprecipitated 125I-VEGF165 and 125I-PlGF-2 in the presence of the b1b2 but not of the a

45 nhanced the binding of both 125I-VEGF165 and 125I-PlGF-2 to the b1b2 domain by 20- and 4-fold, respec

46 cipitation experiments with 125I-VEGF165 and 125I-PlGF-2.

47 ." Two radioiodinated probes, [125I]10a and [125I]10b, and two radiofluorinated probes, [18F]17a and

48 the brain showed that both [(125)I]18a and [125I]18b labeled these brain sections, but [125I]13, sel

49 inhibition of striatal 125I-epibatidine and [125I]A-85380 binding with alpha-CtxMII suggest that ther

50 2 weeks decreased both 125I-epibatidine and [125I]iodo-3-[2(S)-azetidinylmethoxy]pyridine (A-85380) b

51 ography shows cell nuclear [3H]estrogen and [125I]estrogen uptake according to a distribution that pr

52 ese data indicate that [125I]IAPEGlyMER and [125I]TBZ-AIPP are effective photoaffinity labels for VMA

53 er-free radioiodinated [125I]IAPEGlyMER and [125I]TBZ-AIPP were synthesized and used to photoaffinity

54 assayed with [3H]prazosin, [3H]RX21002 and [125I]-iodo-pindolol autoradiography, respectively.

55 with a high affinity Kv1 channel antagonist, 125I-alpha-dendrotoxin.

56 We applied 125I-radioprobing to determine the conformation of the t

57 Cholesterol is found in the same fraction as 125I-Tf on sucrose density gradients, and this fraction

58 led binding of 5-HT(1a) receptors as well as 125I-LSD-labeled binding of 5-HT(2a) receptors were eval

59 In equilibrium binding assays, 125I-N6-aminobenzyladenosine (125I-ABA) binds to two aff

60 In solid phase binding assays, 125I-TIGR/MYOC bound fibronectin but not laminin or type

61 photoaffinity label 3-iodo-4-azidococaine ([125I]IACoc) binds to the sigma-1 receptor with an affini

62 determinant for AppBp1-Uba3 binding because 125I-UbR72L undergoes heterodimer-catalyzed hyperbolic H

63 In beta2M1, [125I]TID labeled beta2-Cys220, which is homologous to al

64 We find here that cells also bind 125I-recombinant CF50, with a Hill coefficient of approx

65 nd the Link module of TSG-6 (Link_TSG6) bind 125I-TSP1 with comparable affinities.

66 ized to the plasma membrane but did not bind 125I-ACTH or increase cAMP in response to ACTH.

67 ; and (3) a residual pool that does not bind 125I-PFO* even after sphingomyelinase treatment.

68 functional in terms of its capacity to bind 125I-labeled C3a and generate inositol triphosphate.

69 Da product that retained the ability to bind 125I-MK-801 and is predicted to be active.

70 M cholesterol: (1) a pool accessible to bind 125I-PFO*, a mutant form of bacterial Perfringolysin O,

71 ither b1 nor b2 alone was capable of binding 125I-VEGF165.

72 phingomyelin(SM)-sequestered pool that binds 125I-PFO* only after SM is destroyed by sphingomyelinase

73 Both 125I-T4 and 3H-cyclosporin accumulation increased by 80%

74 tered twice daily for 2 weeks decreased both 125I-epibatidine and [125I]iodo-3-[2(S)-azetidinylmethox

75 Heparin enhanced the binding of both 125I-VEGF165 and 125I-PlGF-2 to the b1b2 domain by 20- a

76 Receptor-bound 125I-TGF-beta1 undergoes nystatin-inhibitable rapid degr

77 ibitable rapid degradation of receptor-bound 125I-TGF-beta1), treatment with heparitinase or a hepara

78 HARE and the 315-kDa HARE specifically bound 125I-HA.

79 tion, whereas about 70% of the surface-bound 125I-HDL3 was released back into the medium.

80 More than 90% of the surface-bound 125I-LDL was destined for internalization and degradatio

81 In brain, 125I-T4 showed greatest accumulation in the CP (1.52+/-0

82 [125I]18b labeled these brain sections, but [125I]13, selective for Abeta(1-40) aggregates, exhibited

83 sity in monocyte progenitors was assessed by 125I macrophage colony-stimulating factor binding assay.

84 on AP/BL AT1R distribution as determined by 125I-angiotensin II binding in LLCPK(Cl4) cells transfec

85 of proteasome chymotrypsin-like subunits by 125I-YL3-VS demonstrates that REGgamma(K188E)'s activati

86 The labeling by [125I]IAPEGlyMER was blocked by 100 nM reserpine, 10 micr

87 tetrabenazine-protectable photolabeling by [125I]IAmF.

88 an SERT, DAT, and NET using [3H]citalopram, [125I]RTI-55, and [3H]nisoxetine, respectively.

89 d in vivo was assessed by CEA concentration, 125I-uptake, and 123I-imaging studies.

90 In contrast, 125I-MAA-Alb was only partially inhibited with advanced

91 here present a method in which conventional 125I-labeled RIA ([125I] RIA) is adapted to a microtiter

92 y workup, we predict that most conventional [125I] RIAs can be adapted to the mini-RIA format.

93 on of P-gp substrate verapamil increased CSF 125I-T4 recovery to 51.4+/-2.8%, although mrp1 and oatp

94 CR4 with an IC(50) value of 13 nM in a CXCR4 125I-SDF inhibition binding assay.

95 HARE cell lines could endocytose and degrade 125I-HA.

96 terpeduncular tract, where alpha3-dependent [125I]alpha-CtxMII binding was observed.

97 10 or 30 mg/kg) inhibited dose-dependently [125I]sauvagine binding selectively at brain sites of CRF

98 t is conjugated to the 8D3 mAb is designated 125I-PNA/8D3.

99 rifluoromethyl)-3-(m-iodophenyl) diazirine ([125I]TID) and exposed to agonist for either 0 ms (closed

100 uoromethyl-3-(m-[125I]iodophenyl)diazirine ([125I]TID) to determine functionality.

101 oromethyl)-3-(m-[125I]iodophenyl)diazirine ([125I]TID).

102 ability of other peptide mutants to displace 125I-M12A at a concentration of 100 nm.

103 5-HT-displaceable [125I]3beta-(4-iodophenyl)-tropane-2beta-carboxylic acid

104 When purified, it competitively displaced 125I-Cry11Ba binding to An. gambiae BBMV and bound Cry11

105 talytic domain of factor XIa also displaced [125I]factor XIa from the surface of activated platelets

106 human CCR1 with a Kd of 9.2 nm and displaces 125I-labeled CCL3 from CCR1-transfected cells with an IC

107 ailing human hearts was measured with either 125I-Ang I or 125I-Ang II as substrate.

108 Employing 125I-polyubiquitin chain formation as a functional reado

109 ic acid, 4'-azido-3'-iodophenylethyl ester ([125I]RTI 82).

110 Cla-1-associated 3H-LPS uptake exceeded 125I-apolipoprotein uptake by 5-fold indicating a select

111 re cortical AT1 and AT2 receptor expression, 125I-Ang II glomerular binding, tissue renin activity, t

112 d not reduce the initial rate of binding for 125I-alpha-bungarotoxin.

113 Competition for 125I-ABOPX (125I-3-(4-amino-3-iodobenzyl)-8-(phenyl-4-ox

114 Apparent dissociation constants for 125I-SS14 binding to hSST2 were obtained with each metho

115 atriuretic peptide had greater affinity for [125I]-DNP binding sites than C-type natriuretic peptide

116 ons (4.03, 6.22, 5.43, and 8.04% dose/g for [125I]13a, 13b, 16a, and 16b, respectively).

117 15 amino acid residues of the receptor for [125I]IACoc photolabeling.

118 terminal N-acetylgalactosamine required for [125I]Cry1Ac binding in ligand blots.

119 which can reset the high affinity state for [125I]IAAP binding without any further nucleotide hydroly

120 d a rapid 50-150% increase in de novo formed 125I-ubiquitin conjugates.

121 Ang-(1-7)-forming activity from 125I-Ang I was inhibited by thiorphan.

122 ignificantly increased pulmonary and hepatic 125I albumin leak compared with enteral feeding without

123 Maximum 125I-Ang II (125I-Ang II) binding (Bmax) was increased in LP rats (co

124 Anti-Myc antibodies immunoprecipitated 125I-VEGF165 and 125I-PlGF-2 in the presence of the b1b2

125 30% of control) had a 40 to 50% decrease in 125I-epibatidine binding.

126 CCK-2 receptor mRNA abundance and increased 125I-gastrin binding was demonstrated in IEC-6 cells fol

127 ut not indomethacin) significantly increased 125I-T4 accumulation, implicating a role for P-gp and oa

128 oral administration to rats, MTIP inhibited 125I-sauvagine binding to rat cerebellar membranes ex vi

129 l-imidazo [1,2-b]pyridazine (MTIP) inhibited 125I-sauvagine binding to rat pituitary membranes and cl

130 e strongly reduced brain efflux of injected [125I] Abeta(1-42).

131 port substrate [125I]iodoarylazidoprazosin ([125I]IAAP), resulting in dissociation of the latter.

132 '-dimethylaminophenyl)-6-iodobenzothiazole, [125I]7(TZDM), a known ligand for A beta aggregates, with

133 ta-D-arabinofuranosyl)-5-[125I] iodouracil ([125I]FIAU) within bacteria.

134 isproportionate decrease in uptake at lower [125I]AHIgG doses.

135 g photolabeling with 3-trifluoromethyl-3-(m-[125I]iodophenyl)diazirine ([125I]TID) to determine funct

136 hydrophobic probe 3-(trifluoromethyl)-3-(m-[125I]iodophenyl)diazirine ([125I]TID).

137 pophilic reagent, 3'-(trifluoromethyl)-3-(m-[125I]iodophenyl)diazirine, to label proteins in the oute

138 ne-specific probe, 3-(trifluoromethyl)-3-(m-[125I]iodophenyl)diazirine.

139 reater than those of 99mTc-sestamibi, making 125I-iodorotenone the superior flow tracer in the isolat

140 Maximum 125I-Ang II (125I-Ang II) binding (Bmax) was increased i

141 given 1 ml NTS and 12.5, 6.25, and 3.125 mg [125I]AHIgG/100 g body wt had increased glomerular uptake

142 lding Km values for ATP (103 +/- 12 microm), 125I-Nedd8 (0.95 +/- 0.18 microm), and HsUbc12 (43 +/- 1

143 e C5a receptor (C5aR), the binding of murine 125I-C5a to murine neutrophils was reduced, the in vitro

144 hRs are pharmacologically similar to native [125I]alpha-conotoxin MII (alpha-CtxMII)-binding and 3-(2

145 After administration of 125I, the rate of both its secretion from the thyroid gl

146 caveolin-1 cDNA did not alter the amount of 125I-labeled HDL that associated with the cells, althoug

147 etion-variant VPAC2 bound the same amount of 125I-VIP with similar affinity.

148 Autoradiographic analysis of 125I-LSD-labeled 5-HT(2a) receptor binding revealed no s

149 The association of 125I-ABA to high-affinity receptors on Chinese hamster o

150 No binding of 125I-A-85380 was detected, indicating the absence of bet

151 Cross-linking studies measuring binding of 125I-activin-A to the ALK4-trunc mutants in the presence

152 ncreased C5L2 protein (defined by binding of 125I-anti-C5L2 IgG) occurred in lung, liver, heart, and

153 seven leucine-rich repeats on the binding of 125I-FXI to activated platelets.

154 Total cellular binding of 125I-Hst 5 in the ssa2Delta mutant was reduced to one-th

155 Binding of 125I-labeled anti-C5aR to lung, liver, kidney, and heart

156 ls showed significantly increased binding of 125I-labeled anti-C5aR to organs when compared to either

157 (Cpd 1), a compound that inhibits binding of 125I-labeled glucagon to the human glucagon receptor wit

158 ctable by flow cytometry, and the binding of 125I-labeled IP-10/CXCL10 to these cells was not compete

159 fic, saturable, and high affinity binding of 125I-labeled recombinant rat C5a.

160 Moreover, the binding of 125I-labeled thrombin to glycocalicin was unaffected by

161 e3 yielded a peptide that reduced binding of 125I-M12A 326-fold.

162 factor-BB and reduced by 40% the binding of 125I-platelet-derived growth factor-BB to fibroblast cel

163 AP, an LRP-1 antagonist, inhibits binding of 125I-TGF-beta1 and 125I-IGFBP-3 to TbetaR-V and diminish

164 we found that SEMA3B competed for binding of 125I-VEGF165 to lung and breast cancer cells.

165 CRFR1 as the cross-linking site for Bpa17 of 125I-[Tyr0, Gln1, Bpa17]SVG.

166 on rate was measured as urinary clearance of 125I-iothalamate.

167 probability of DNA breaks caused by decay of 125I is inversely related to the distance between the ra

168 The degradation of 125I-f-Alb or 125I-MAA-Alb in whole livers and isolated

169 was determined either by the degradation of 125I-labeled OS to trichloroacetic acid-soluble label or

170 ble methyl-4-azidobenzoimidate derivative of 125I-alpha-bungarotoxin.

171 ability to prevent the rapid dissociation of 125I-ABA from A1AR in response to GTPgammaS.

172 oautoradiographic studies show expression of 125I-labeled iodo-deschloroepibatidine binding sites in

173 r Kv1.6 antibodies by immunoprecipitation of 125I-alpha-dendrotoxin-labelled rabbit brain K+ channels

174 77 cells resulted in 3-4.4-fold increases of 125I-low density lipoprotein (LDL) and 125I-high density

175 However, modest inhibition of 125I-Nedd8 ternary complex formation by unlabeled ubiqui

176 xpressing LRP mediate the internalization of 125I-labeled MMP-9.TIMP-1 complexes, whereas cell lines

177 reporter function to probe the mechanism of 125I-ubiquitin transfer between activation and ligation

178 n had a specific activity of 3.9 micromol of 125I-alpha-bungarotoxin binding sites/g of protein.

179 Placement of 125I seeds did not interfere with lymphoscintigraphy or

180 s including decreasing polyubiquitylation of 125I-lysozyme by removing ubiquitin from polyubiquitin c

181 se receptor-binding assay in the presence of 125I-echistatin.

182 ange from a low (<1) to a high (>1) ratio of 125I-TGF-beta1 binding to TbetaR-II and TbetaR-I and enh

183 lls exhibit low (<1) and high (>1) ratios of 125I-TGF-beta1 binding to TbetaR-II and TbetaR-I, respec

184 The extraction and retention of 125I-iodorotenone were greater than those of 99mTc-sesta

185 P-gp and oatps contribute to the transfer of 125I-T4 between the CSF, CP and brain, hence regulating

186 The uptake of 125I-B72.3 in LS174T xenografts increased in a dose-depe

187 nd completely blocked the specific uptake of 125I-HA at 37 degrees C by rat liver sinusoidal endothel

188 eceptors enhances megalin-mediated uptake of 125I-lactoferrin, a megalin ligand.

189 Analysis of [125I]TBZ-AIPP-labeled chromaffin granule membranes by SD

190 lysis of nAChR currents, autoradiography of [125I]-alpha-bungarotoxin binding, and in situ hybridizat

191 rank order of potency suggested binding of [125I]-DNP was specific to NPR-A.

192 as indicated by specific ligand binding of [125I]-RTI-55.

193 Binding of [125I]A-312110 to guinea pig cardiac (KD = 5.8 nM) and ur

194 in (Ile370-Val607) inhibited the binding of [125I]factor XIa to the platelets (Ki approximately 3.5 n

195 vo autoradiography revealed that binding of [125I]sauvagine, a mixed CRH1/CRH2 agonist, was prevented

196 Displacement of [125I]A-312110 by structurally diverse potassium channel

197 CNBr hydrolysis of [125I]RTI 82-labeled rat striatal and expressed human DAT

198 Incubation of [125I]TBZ-AIPP-photolabeled chromaffin granule membranes

199 tribution after an intravenous injection of [125I]16(IMPY) in normal mice showed a high initial brain

200 The interaction of [125I]IAmF with VMAT2 is highly dependent on the presence

201 The final localization of [125I]RTI 82 incorporation to rat DAT Met(290)-Lys(336) a

202 affect expression of the great majority of [125I]alpha-CtxMII-binding sites, indicating that they do

203 ely related analogs, induce regeneration of [125I]IAAP binding to vanadate-trapped (or fluoroaluminat

204 ts indicate that this stimulated release of [125I]BDNF is not regulated by a feedback mechanism media

205 The release of [125I]BDNF was found to be dependent on the concentration

206 ed activity-dependent short-term release of [125I]BDNF.

207 near the carboxyl terminus, as the site of [125I]IACoc insertion.

208 Flow had less effect on 125I-iodorotenone net retention than on 99mTc-sestamibi

209 ed 1,4-dihydropyridine KATP channel opener, [125I]A-312110 [(9R)-9-(4-fluoro-3-125iodophenyl)-2,3,5,9

210 The degradation of 125I-f-Alb or 125I-MAA-Alb in whole livers and isolated SECs can be in

211 formaldehyde-bovine serum albumin (f-Alb) or 125I-malondialdehyde-acetaldehyde-bovine serum albumin (

212 ubated with 125I-labeled FVIII C2 domain, or 125I-FVIIIa, or 125I-FVIII((LC)), or peptides from the C

213 active (IR) binding of either labeled Epb or 125I-alpha-conotoxin MII increased to a much greater ext

214 -labeled FVIII C2 domain, or 125I-FVIIIa, or 125I-FVIII((LC)), or peptides from the C2 domain region,

215 earts was measured with either 125I-Ang I or 125I-Ang II as substrate.

216 Using unlabelled or 125I-labelled Osp proteins, Osp-specific monoclonal anti

217 f CaGC to native and recombinant paramyosin, 125I-CaGC was used as a binding tracer in SDS-PAGE analy

218 l 2.87 +/- 0.85 versus LP 0.84 +/- 0.20 pmol 125I-Ang II, P = 0.059).

219 The precise [125I]IACoc derivatization site in the guinea pig sigma-1

220 n of the SPECT and PET probes with preformed 125I-labeled thrombi and with a nonbinding control probe

221 ghest doses, NBI 35965 completely prevented [125I]sauvagine labeling in the cortex.

222 An angiotensin analog, photoaffinity probe 125I-SBpa-Ang II, was used to specifically label the non

223 lick chemistry." Two radioiodinated probes, [125I]10a and [125I]10b, and two radiofluorinated probes,

224 hroughput screening methods for quantitating 125I-SS14 binding to human somatostatin receptor 2 (hSST

225 h or CLP animals infused with normal rabbit 125I-labeled IgG.

226 Carrier-free radioiodinated [125I]IAPEGlyMER and [125I]TBZ-AIPP were synthesized and

227 fold less potent at human 5-HT2A receptors ([125I]DOI) with a derived Ki value of 18 nM and 20-fold l

228 ween the CSF, CP and brain, hence regulating 125I-T4 availability in CSF.

229 pyridine dihydrochloride (A85380)-resistant [125I]epibatidine-binding nAChR subtypes, respectively.

230 wer levels of alpha3-independent -resistant [125I]epibatidine binding were also seen.

231 In contrast, most -resistant [125I]epibatidine-binding nAChRs were dependent on alpha3

232 hod in which conventional 125I-labeled RIA ([125I] RIA) is adapted to a microtiter plate format, term

233 Within the alpha4M1 segment, [125I]TID labeled residues Cys226 and Cys231, which corre

234 Within M4 segments, [125I]TID labeled homologous amino acids alpha4-Cys582/be

235 horesis (SDS-PAGE) analysis showed specific [125I]IAPEGlyMER labeling of a polypeptide that migrated

236 alpha-CtxMII inhibition of striatal 125I-epibatidine and [125I]A-85380 binding with alpha-Ct

237 affinity of Pgp for its transport substrate [125I]iodoarylazidoprazosin ([125I]IAAP), resulting in di

238 ting the binding of a known P-gp substrate, [125I]iodoarylazidoprazosin.

239 on mesangial or reticuloendothelial system [125I]AHIgG uptake.

240 by triplex-forming oligonucleotide-targeted 125I decay.

241 ollectively, these results demonstrate that [125I]A-312110 binds with high affinity and has an improv

242 In vitro studies demonstrated that [125I]sauvagine binding in the LS could be inhibited by a

243 Taken together, these results indicate that [125I]BDNF release is activity dependent, and is modulate

244 These data indicate that [125I]IAPEGlyMER and [125I]TBZ-AIPP are effective photoaf

245 also demonstrated, for the first time, that [125I]iodoarylazidoprazosin, a photoaffinity analog of th

246 The 125I-PNA/8D3 conjugate was administered intravenously to

247 eceptor family, alpha2A and alpha2C, and the 125I-labeled agonist clonidine.

248 Finally, the 125I/111In biodistribution data allowed for dose estimat

249 tering proximal to the DSB resulted from the 125I decays responsible for DSB formation and was not du

250 internal control fragment recovered from the 125I linearized plasmid did not exhibit endo IV sensitiv

251 Metabolism of the 125I-labeled scFv-Fc proteins resulted in low normal org

252 4Cu-D-Cys-FBP8, detected the location of the 125I-labeled thrombus, confirming high target specificit

253 ed a 3-fold increase in sequestration of the 125I-PNA/8D3 antisense radiopharmaceutical in the brains

254 lustering of AP sites within 10 bases of the 125I-targeted base in the DNA duplex.

255 Regeneration of the [125I]IAAP site requires an additional round of nucleotid

256 Cyanogen bromide cleavage of the [125I]IACoc photolabeled sigma-1 receptor followed by rad

257 a2-Cys445, which are also homologous to the [125I]TID-labeled residues alpha1-Cys418 and beta1-Cys447

258 Cys226 and Cys231, which correspond to the [125I]TID-labeled residues Cys222 and Phe227 at the lipid

259 d, the substrate site remains accessible to [125I]IAAP even after removal of the modulator from the m

260 Wild type 125I-ubiquitin fails to support AppBp1-Uba3 catalyzed ac

261 f tightly bound Nedd8 [3H]adenylate and Uba3-125I-Nedd8 thiol ester.

262 ect expression of nAChRs in monkeys, we used 125I-epibatidine, an agonist at nAChRs containing alpha2

263 Using 125I-labeled annexin II binding to screen NIH3T3 transfe

264 dsorption and release was accomplished using 125I radiolabeled growth factor.

265 Previously, a functional assay using 125I-labeled F-actin to detect a subset of F-actin bindi

266 construct and performed binding assays using 125I-human UG (hUG).

267 Solid phase binding assays using 125I-recombinant TIGR/MYOC and types I and IV collagens,

268 ting and gel filtration chromatography using 125I-labeled proteins.

269 ood after preincubation was determined using 125I-LPS.

270 type or mutant AChR subunits, we show, using 125I-alpha-bungarotoxin binding and immunofluorescence t

271 Binding assays using [125I]-Hb revealed that the bipartite receptor has a sing

272 g kg(-1), pentobarbitone 10 mg kg(-1) i.v.), 125I-T4 was perfused continuously into ventricular CSF w

273 With 125I-Ang II as substrate, Ang-(1-7) formation was inhibi

274 Angiotensinase activity with 125I-Ang I as substrate was increased in failing IDC lef

275 Ang-(1-7)-forming activity with 125I-Ang II as substrate was increased in both failing L

276 Dual autoradiography with 125I-bovine serum albumin as a control showed that 99mTc

277 nd used in co-precipitation experiments with 125I-VEGF165 and 125I-PlGF-2.

278 ide, SFLLRN (25 microM), were incubated with 125I-labeled FVIII C2 domain, or 125I-FVIIIa, or 125I-FV

279 muscle was not seen in rabbits injected with 125I-labeled human serum albumin (n=6).

280 homologous (normal) fibrinogen, labeled with 125I and 121I, respectively, were performed in two affec

281 SS1scFvSA was labeled with 125I or 111In for evaluation of internalization in vitro

282 In cells labeled with 125I-Ang II, WT treatment did not impair the rate of rec

283 s, acute hyperpermeability was measured with 125I-albumin, and cytokines and myeloperoxidase activity

284 s used as the other competition partner with 125I-[MePhe7]NKB as the radioligand, indicating competit

285 13b, 16a, 16b, and 16e (radioiodinated with 125I) were successfully prepared.

286 Boronated EGF was radiolabeled with 125I and administered by CED at a rate of 0.33 micro l/m

287 ne residue, which enables radiolabeling with 125I.

288 udies, rat livers were perfused in situ with 125I-formaldehyde-bovine serum albumin (f-Alb) or 125I-m

289 Clearance studies with 125I-labeled 4-GSP-6 demonstrated rapid reduction in its

290 n NHEKs was verified by binding studies with 125I-VEGF.

291 3H]EB) is approximately 30% higher than with 125I-3-(2(S)-azetidinylmethoxy)pyridine (A-85380) and mo

292 y labeling of the multidrug transporter with 125I-iodoarylazidoprazosin and [3H]azidopine.

293 ic kinetics for HsUbc12 transthiolation with 125I-Nedd8 (kcat = 3.5 +/- 0.2 s-1), yielding Km values

294 ein (Ki approximately 2.7 nM) competed with [125I]factor XIa for binding sites on activated platelets

295 onist high affinity state was examined with [125I]-para-iodoclonidine autoradiography and alpha2-AR f

296 ra of bacteria could be readily imaged with [125I]FIAU.

297 ion of brainstem sections preincubated with [125I]p-iodoclonidine revealed no inter-strain difference

298 The slices were preloaded with [125I]BDNF and exposed to depolarising stimulation with v

299 ections of a transgenic mouse (Tg2576) with [125I]16(IMPY) displayed high selective binding to amyloi

300 HTB-81 cells with the same construct yielded 125I-hUG binding with high affinity (Kd=18 nM) and speci